Approval Milestone. Within thirty (30) days of the achievement of the Approval Milestone Event (as defined in the Equity Agreement), Ampliphi will pay to Intrexon, according to the timelines and procedures set forth in the Equity Agreement, one of the following: (i) [*****] in cash, or (ii) the Approval Milestone Shares (as defined in the Equity Agreement).
Approval Milestone. BioForm shall pay to Supplier a milestone payment equal to $500,000 upon BioForm receiving the first PMA approval from the FDA to market and sell the Company Product in any application within the Field in the United States.
Approval Milestone. Within thirty (30) days after the date on which Ligand receives notice that the United States Food and Drug Administration ("FDA") has given final approval of the labeling for the Biologics License Application ("BLA") for Ontak(TM), Ligand shall issue that number of shares (the "Approval Shares") of its voting common stock to Lilly as shall equal the sum of $10 million divided by the average trading price of Ligand's voting common stock over the twenty (20) consecutive trading days immediately preceding the date which is five (5) consecutive days prior to the date the notice referred to above is received.
Approval Milestone. Within thirty (30) days after the date on which Ligand receives notice that the United States Food and Drug Administration ("FDA") has given final approval of the labeling for the [ * ] Ligand shall issue that number of shares (the "Approval Shares") of its voting common stock to Lilly as shall equal the sum of $10 million divided by the average trading price of Ligand's voting common stock over the twenty (20) consecutive trading days immediately preceding the date which is five (5) consecutive days prior to the date the notice referred to above is received.
Approval Milestone. Hoth will pay Chelexa a one-time cash fee of $3.5 million upon either (i) the first license in the U.S., any U.S. territory or the European Union to make, use and sell a Licensed Product in such country or territory, or (ii) the receipt of approval from the United Stated Federal Drug Administration (FDA) to make, use and sell a Licensed Product.
Approval Milestone. Within ten (10) business days after the receipt by Amgen (or any of its Affiliates or Sublicensees) of the first Regulatory Approval of an [*****] for the first Product by the applicable Regulatory Authority in any Major Market (the “Approval Milestone”), Amgen shall notify Company in writing of such occurrence. Thereafter, Amgen will pay to the Company milestone payment of an amount of cash equal to [*****] Dollars ($[*****]) (the “Milestone Payment”) within forty five (45) days of its delivery of notice thereof. The Milestones Payment is non-creditable and non-refundable and shall be due and payable upon the occurrence of the Approval Milestone regardless of any failure by Amgen to provide the notice required by Section 7.1(b). For clarity, the Milestone Payment is payable only once.
Approval Milestone. Milestone EventMilestone Payments First Regulatory Approval of the Licensed Product by the FDA for the DD-CKD indication Fifty million U.S. dollars (USD $50,000,000), by Vifor purchasing fifty million U.S. dollars (USD $50,000,000) in Cara common stock, pursuant to the terms of the Stock Purchase Agreement entered into by Cara and Vifor concurrently with this Agreement, at the purchase price as set in that agreement CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE CARA THERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO CARA THERAPEUTICS, INC. IF PUBLICLY DISCLOSED.
Approval Milestone. Within [*****] following the first Regulatory Approval of the Product in the Field in any country of the Additional Defiante Territory, Defiante shall pay to Dyax a one-time milestone payment in the amount of [*****].
Approval Milestone. Within [*****] following Regulatory Approval in Defiante’s name of the Product for the HAE Indication by the EMA, Defiante shall pay to Dyax a one-time milestone payment in the amount of [*****].
Approval Milestone. Upon receipt of the first approval by the FDA or the European Medicines Agency of the marketing and sale by Purchaser or any of its Subsidiaries or Licensees of an Earn-Out Product in the United States, France, Germany, Italy, Spain or the United Kingdom prior to the fifteen (15) year anniversary of the Closing Date (the “Approval Milestone” and, together with the IND Milestone and the POC Milestone, the “Development Milestones”), Purchaser shall pay to the Sellers fifty million dollars ($50,000,000) (the “Approval Milestone Payment” and, together with the IND Milestone Payment and the POC Milestone Payment, the “Development Milestone Payments”) in accordance with this Section 1.8.
